A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions: DRUG: Giredestrant|DRUG: Fulvestrant|DRUG: Abemaciclib|DRUG: Palbociclib|DRUG: Ribociclib|DRUG: LHRH Agonist|DIAGNOSTIC_TEST: FoundationOne Liquid CDx Assay (F1LCDx)
Sponsor: Hoffmann-La Roche